Krystal Biotech Inc (KRYS)
Days of sales outstanding (DSO)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Receivables turnover | 2.80 | 2.55 | 1.67 | 2.23 | 1.38 | 1.17 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| DSO | days | 130.27 | 143.32 | 218.43 | 163.38 | 263.86 | 310.65 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
December 31, 2024 calculation
DSO = 365 ÷ Receivables turnover
= 365 ÷ 2.80
= 130.27
The Days Sales Outstanding (DSO) ratio for Krystal Biotech Inc has shown a fluctuating trend over the past few years. As of December 31, 2023, the DSO stood at 263.86 days before dropping significantly to 163.38 days by March 31, 2024. This indicates that the company has been more efficient in converting its accounts receivable into cash during this period.
The DSO further improved by June 30, 2024, reaching 218.43 days, reflecting a slower collection of receivables compared to the previous quarter. However, by September 30, 2024, the DSO decreased significantly to 143.32 days, suggesting a heightened collection efficiency.
As of the latest data available, as of December 31, 2024, the DSO stands at 130.27 days, indicating a further improvement in the company's ability to collect outstanding receivables in a timely manner. Overall, the trend in DSO suggests that Krystal Biotech Inc has been managing its accounts receivable effectively and enhancing its cash flow management.
Peer comparison
Dec 31, 2024